News + Filings Transactions Holdings
All 13F 13D/G Other
|
RA CAPITAL MANAGEMENT, L.P.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/11/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 33.7% stake in VOR BIOPHARMA INC. |
08/11/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 16.7% stake in 89BIO, INC. |
08/09/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in DICE THERAPEUTICS, INC. |
07/25/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
06/12/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Satsuma Pharmaceuticals, Inc. |
05/30/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 12.5% stake in Icosavax, Inc. |
04/18/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
03/29/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
01/10/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 18% stake in Werewolf Therapeutics, Inc. |
12/30/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
12/23/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 7.3% stake in ACHILLES THERAPEUTICS PLC |
12/15/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
12/09/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
12/05/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 17.6% stake in SOLID BIOSCIENCES INC. |
11/14/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
10/21/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
10/19/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
10/14/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in FORMA THERAPEUTICS HOLDING, INC. |
10/04/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 11% stake in SOLID BIOSCIENCES INC. |
09/26/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in POINT BIOPHARMA GLOBAL INC. |
09/16/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 8.6% stake in POINT BIOPHARMA GLOBAL INC. |
09/06/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 11% stake in SOLID BIOSCIENCES INC. |
09/02/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 18.9% stake in FORMA THERAPEUTICS HOLDING, INC. |
08/29/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.9% stake in POINT BIOPHARMA GLOBAL INC. |
08/12/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 14.6% stake in Werewolf Therapeutics, Inc. |
07/06/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
06/23/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
06/21/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
06/03/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
05/31/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 8.5% stake in Kala Pharmaceuticals, Inc. |
05/25/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
05/02/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 16.2% stake in Nkarta, Inc. |
04/01/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 15% stake in Kala Pharmaceuticals, Inc. |
03/14/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.8% stake in Cytek BioSciences, Inc. |
|
|
|